Meet NMIN’s Commercialization Advisory Board (CAB)

Top L to R: Brenna Rauw, Stephen Dibert, Inès Holzbaur, Wendy Lamson. Bottom L to R: Lihn Le, Helen Loughrey, Paul Santerre, Andrew Sinclair, Gary Skarja.

The NanoMedicines Innovation Network (NMIN) is pleased to introduce the inaugural members of its Commercialization Advisory Board (CAB).

The Commercialization Advisory Board (CAB) provides arm’s-length, expert review and assessment of the funding eligibility of applications to NMIN’s Strategic Initiative (SI) KTEE/Commercialization Support program. It also provides advice and mentorship to NMIN investigators seeking to commercialize their network-supported intellectual property (NSIP). Its inaugural members are:
  • CHAIR: Brenna Rauw, Founder and Managing Director, 12Bridge
  • Stephen Dibert, Strategic Advisor – Life Sciences, Medtech Canada; CEO, TOHealt
  • Inès Holzbaur, Co-Founder & Managing Partner, AmorChem
  • Wendy Lamson, Partner and Patent Agent, Perley-Robertson, Hill & McDougall
  • Linh Le, Founder and CEO, Flextrapower Technologies
  • Helen Loughrey, Health Challenge Officer, National Research Council Canada
  • Paul Santerre, Professor & Baxter Chair in Health Technology & Commercialization (UHN), University of Toronto
  • Andrew Sinclair, Technology Executive
  • Gary Skarja, Head of Membrane Chromatography R&D, MilliporeSigma